Liberia has commenced the first large-scale trials of an experimental Ebola vaccine.
Scientists aim to immunize around 30,000 volunteers and health care workers in the country starting Monday, the BBC reports. The trial will involve injecting each of them with a tiny amount of chimpanzee cold virus that carries safe genetic material of Ebola, tricking the human body into producing an immune response.
The medicine has been hidden in a secret location in the country since it arrived one week ago.
British pharmaceutical and healthcare company GlaxoSmithKline developed the vaccine alongside the U.S. National Institutes of Health; should the trial be successful, it would be the first preventative vaccine against the killer virus.
More than 8,500 people have died during the current Ebola outbreak, with 3,600 succumbing to the disease in Liberia alone. The number of new Ebola cases is in steady decline, however.
[BBC]
More Must-Reads from TIME
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
Write to Helen Regan at helen.regan@timeasia.com